Onkološki inštitut Ljubljana je osrednja slovenska zdravstvena ustanova za področje onkologije; tako nudi sekundarno in terciarno zdravljenje ter izobraževalno-raziskovalno dejavnost.

During the past decade, Institute of Oncology Ljubljana conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 19 clinical trials were completed, i.e. on average, 67.9% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 9 clinical trials were completed. i.e. 81.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Oncology Ljubljana" #1 sponsor was "Institute of Oncology Ljubljana" with 20 trials, followed by "Hoffmann-La Roche" with 17 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 16 trials sponsored, "ETOP IBCSG Partners Foundation" with 7 trials sponsored and "Central European Cooperative Oncology Group" with 7 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Oncology Ljubljana" #1 collaborator was "Breast International Group" with 3 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "University Medical Centre Ljubljana" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Oncology Ljubljana" are "Breast Cancer" (17 trials), "Metastatic Colorectal Cancer" (4 trials), "Rectal Cancer" (4 trials), "Head and Neck Cancer" (3 trials) and "Lymphoma" (3 trials). Many other conditions were trialed in "Institute of Oncology Ljubljana" in a lesser frequency.

Most popular intervention types in "Institute of Oncology Ljubljana" are "Drug" (56 trials), "Radiation" (13 trials), "Procedure" (12 trials), "Other" (10 trials) and "Biological" (9 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (7 trials), "Paclitaxel" (6 trials), "Placebo" (6 trials), "radiation therapy" (6 trials) and "Docetaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Oncology Ljubljana" are 63 trials for "All" genders, 17 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Institute of Oncology Ljubljana". undefined are not yet recruiting, 9 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in Institute of Oncology Ljubljana, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Oncology Ljubljana, 5 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".